Hemostemix Inc. (HEM.V)
TSXV · CAD · Healthcare · Biotechnology
CA$0.055 (+0.00%) as of
Key statistics
- Market cap
- 11.63M
- Forward P/E
- -0.39
- EPS (TTM)
- -0.0200
- Dividend yield
- 0.00%
- 52-week range
- 0.0400 – 0.1100
- Beta
- 0.73
- Profit margin
- 0.00%
- Volume
- 6.30k
About Hemostemix Inc.
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Calgary, AB, Canada
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.